In vitro selection of Plasmodium falciparum drug-resistant parasite lines

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2009, Pages 390-398

  Nzila, Alexis ^a,b   Mwai, Leah ^a,b  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

'Accelerated resistance to multidrug'; Clones; Mutation rate; Per parasite resistant frequency; Resistance indexes

Indexed keywords

ANTIPROTOZOAL AGENT; ATOVAQUONE; AZITHROMYCIN; BMS 3888891; BMS 388891; CHLOROQUINE; CYCLOGUANIL; FLUOROOROTIC ACID; HALOFANTRINE; MEFLOQUINE; PYRIMETHAMINE; QUININE; SULFADOXINE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CONCENTRATION RESPONSE; IC 50; IN VITRO SELECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; QUALITY CONTROL; REVIEW; TIME;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; PARASITOLOGY; PLASMODIUM FALCIPARUM; SELECTION, GENETIC;

EID: 77950309299     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp449     Document Type: Review

References (71)

1. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320: 330-4.
2. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113: 1084-92.
3. Peters W. Chemotherapy and Drug Resistance in Malaria. London: Academic Press, 1987.
4. Afonso A, Hunt P, Cheesman S et al. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother 2006; 50: 480-9.
5. Carlton JM, Hayton K, Cravo PV et al. Of mice and malaria mutants: unravelling the genetics of drug resistance using rodent malaria models. Trends Parasitol 2001; 17: 236-42.
6. Hunt P, Afonso A, Creasey A et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol 2007; 65: 27-40.
7. Hunt P, Cravo PV, Donleavy P et al. Chloroquine resistance in Plasmodium chabaudi: are chloroquine-resistance transporter (crt) and multi-drug resistance (mdr1) orthologues involved? Mol Biochem Parasitol 2004; 133: 27-35.
8. Hunt P, Martinelli A, Fawcett R et al. Gene synteny and chloroquine resistance in Plasmodium chabaudi. Mol Biochem Parasitol 2004; 136: 157-64.
9. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193: 673-5.
10. Nguyen-Dinh P, Trager W. Chloroquine resistance produced in vitro in an African strain of human malaria. Science 1978; 200: 1397-8.
11. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 2007; 8: 75-94.
12. Myint HY, Ashley EA, Day NP et al. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007; 101: 858-66.
13. Ramharter M, Kurth F, Schreier AC et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008; 198: 911-9.
14. Checkley AM, Whitty CJ. Artesunate, artemether or quinine in severe Plasmodium falciparum malaria? Expert Rev Anti Infect Ther 2007; 5: 199-204.
15. Dondorp A, Nosten F, Stepniewska K et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-25.
16. Jones KL, Donegan S, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2007; issue 4: CD005967.
17. Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455-67.
18. Jambou R, Legrand E, Niang M et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005; 366: 1960-3.
19. Witkowski B, Berry A, Benoit-Vical F. Resistance to antimalarial compounds: methods and applications. Drug Resist Updat 2009; 12: 42-50.
20. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18: 458-64.
21. Oduola AM, Milhous WK, Weatherly NF et al. Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp Parasitol 1988; 67: 354-60.
22. Wilson CM, Serrano AE, Wasley A et al. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science 1989; 244: 1184-6.
23. Basco LK. Molecular epidemiology of malaria in Cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Am J Trop Med Hyg 2004; 70: 474-80.
24. Briolant S, Parola P, Fusai T et al. Influence of oxygen on asexual blood cycle and susceptibility of Plasmodium falciparum to chloroquine: requirement of a standardized in vitro assay. Malar J 2007; 6: 44.
25. Preechapornkul P, Imwong M, Chotivanich K et al. Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob Agents Chemother 2009; 53: 1509-15.
26. Peel SA, Merritt SC, Handy J et al. Derivation of highly mefloquine-resistant lines from Plasmodium falciparum in vitro. Am J Trop Med Hyg 1993; 48: 385-97.
27. Brockelman CR, Monkolkeha S, Tanariya P. Decrease in susceptibility of Plasmodium falciparum to mefloquine in continuous culture. Bull World Health Organ 1981; 59: 249-52.
28. Lambros C, Notsch JD. Plasmodium falciparum: mefloquine resistance produced in vitro. Bull World Health Organ 1984; 62: 433-8.
29. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 1994; 91: 1143-7.
30. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005; 94: 181-90.
31. Price RN, Cassar C, Brockman A et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 1999; 43: 2943-9.
32. Price RN, Uhlemann AC, Brockman A et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364: 438-47.
33. Uhlemann AC, McGready R, Ashley EA et al. Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis 2007; 195: 134-41.
34. Barnes DA, Foote SJ, Galatis D et al. Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J 1992; 11: 3067-75.
35. Sanchez CP, Stein WD, Lanzer M. Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum. Trends Parasitol 2007; 23: 332-9.
36. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27: 594-601.
37. Ekland EH, Fidock DA. Advances in understanding the genetic basis of antimalarial drug resistance. Curr Opin Microbiol 2007; 10: 363-70.
38. Cooper RA, Ferdig MT, Su XZ et al. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol Pharmacol 2002; 61: 35-42.
39. Lim AS, Cowman AF. Plasmodium falciparum: chloroquine selection of a cloned line and DNA rearrangements. Exp Parasitol 1996; 83: 283-94.
40. Banyal HS, Inselburg J. Plasmodium falciparum: induction, selection, and characterization of pyrimethamine-resistant mutants. Exp Parasitol 1986; 62: 61-70.
41. Inselburg J, Bzik DJ, Horii T. Pyrimethamine resistant Plasmodium falciparum: overproduction of dihydrofolate reductase by a gene duplication. Mol Biochem Parasitol 1987; 26: 121-34.
42. Tanaka M, Gu HM, Bzik DJ et al. Mutant dihydrofolate reductase-thymidylate synthase genes in pyrimethamine-resistant Plasmodium falciparum with polymorphic chromosome duplications. Mol Biochem Parasitol 1990; 42: 83-91.
43. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005; 57: 117-45.
44. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother 2006; 57: 1043-54.
45. Hawkins VN, Joshi H, Rungsihirunrat K et al. Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol 2007; 23: 213-22.
46. Korsinczky M, Chen N, Kotecka B et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000; 44: 2100-8.
47. Berry A, Senescau A, Lelievre J et al. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans R Soc Trop Med Hyg 2006; 100: 986-8.
48. Musset L, Bouchaud O, Matheron S et al. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect 2006; 8: 2599-604.
49. Pimentel S, Nogueira F, Benchimol C et al. Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola. Malar J 2006; 5: 30.
50. Buckner FS, Eastman RT, Yokoyama K et al. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr Opin Investig Drugs 2005; 6: 791-7.
51. Eastman RT, White J, Hucke O et al. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem 2005; 280: 13554-9.
52. Olepu S, Suryadevara PK, Rivas K et al. 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorg Med Chem Lett 2008; 18: 494-7.
53. Noedl H, Krudsood S, Leowattana W et al. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother 2007; 51: 651-6.
54. Kalilani L, Mofolo I, Chaponda M et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS ONE 2007; 2: e1166.
55. Noedl H, Krudsood S, Chalermratana K et al. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis 2006; 43: 1264-71.
56. Miller RS, Wongsrichanalai C, Buathong N et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg 2006; 74: 401-6.
57. Dunne MW, Singh N, Shukla M et al. A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India. Am J Trop Med Hyg 2005; 73: 1108-11.
58. Dunne MW, Singh N, Shukla M et al. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis 2005; 191: 1582-8.
59. Sidhu AB, Sun Q, Nkrumah LJ et al. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem 2007; 282: 2494-504.
60. Peters W, Porter M. The chemotherapy of rodent malaria, XXVI. The potential value of WR 122,455 (a 9-phenanthrenemethanol) against drug-resistant malaria parasites. Ann Trop Med Parasitol 1976; 70: 271-81.
61. Powers KG, Jacobs RL, Good WC et al. Plasmodium vinckei: production of chloroquine-resistant strain. Exp Parasitol 1969; 26: 193-202.
62. Rosario VE. Genetics of chloroquine resistance in malaria parasites. Nature 1976; 261: 585-6.
63. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997; 94: 9389-93.
64. Trotta RF, Brown ML, Terrell JC et al. Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum. Biochemistry 2004; 43: 4885-91.
65. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 1988; 85: 9114-8.
66. Ramakrishnan SP, Prakash S, Chowdhury DS et al. Studies on Plasmodium berghei Vincke and Lips, 1948. XXIX. The size of parasite population and its relation to the selection of a strain resistant to sulphadiazine. Indian J Malariol 1961; 15: 95-106.
67. Martin DC, Arnold JD. The effect of parasite populations on the curative action of pyrimethamine. Trans R Soc Trop Med Hyg 1968; 62: 379-84.
68. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 2003; 270: 545-54.
69. Daher W, Biot C, Fandeur T et al. Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar J 2006; 5: 11.
70. Aly NS, Hiramoto A, Sanai H et al. Proteome analysis of new antimalarial endoperoxide against Plasmodium falciparum. Parasitol Res 2007; 100: 1119-24.
71. Nkrumah LJ, Riegelhaupt PM, Moura P et al. Probing the multifactorial basis of Plasmodium falciparum quinine resistance: evidence for a strain-specific contribution of the sodium-proton exchanger PfNHE. Mol Biochem Parasitol 2009; 165: 122-31.